Results 291 to 300 of about 4,684,794 (400)

Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy

, 2000
James D. Douketis, Gary Foster, Mark Crowther, Martin H. Prins, J S Ginsberg   +4 more
openalex   +1 more source

Markers of Inflammation and Hypofibrinolysis Are Associated with Cognitive Dysfunction and Motor Performances in Atrial Fibrillation Patients on Oral Anticoagulant Therapy: Insights from the Strat-AF Study. [PDF]

Biomedicines
Alfano F, Cesari F, Gori AM, Berteotti M, Salvadori E, Giusti B, Bertelli A, Fratini F, Rogolino A, Formelli B, Pescini F, Fainardi E, Barucci E, Salti G, Cavaliere A, Ginestroni A, Marcucci R, Poggesi A.   +17 more
europepmc   +1 more source

Racial differences in the utilization of oral anticoagulant therapy in heart failure: A study of elderly hospitalized patients

, 2000
Said A. Ibrahim, C. Kent Kwoh, Dwain L. Harper, David W. Baker   +3 more
openalex   +2 more sources

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

A Case of Cerebral Amyloid Angiopathy With Recurrent Hemorrhagic and Ischemic Strokes Under Direct Oral Anticoagulant Therapy for Atrial Fibrillation. [PDF]

Cureus
Uemura J, Yamashita S, Yagita Y, Inoue T.   +3 more
europepmc   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source

The effect of rivaroxaban as an anticoagulant therapy for acute pulmonary embolism and the predictive role of vascular endothelial markers in assessing anticoagulant efficacy before treatment. [PDF]

Am J Transl Res
Du H, Zheng Q.
europepmc   +1 more source

Topical Anesthesia Cataract Surgery in Patients with Anticoagulant Therapy

, 2000
J.C. Quintyn, Emile Calenda, A Retout, Gérard Brasseur   +3 more
openalex   +1 more source